MDR1 will play a key role in pharmacokinetic changes under hypoxia at high altitude and its potential regulatory networks

References

• Arancibia A, Gai MN, Chavez J, et al. (2005). Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude. Int J Clin Pharmacol Ther 43:85–91
   PubMed Web of Science ®Google Scholar
• Arancibia A, Nella GM, Paulos C, et al. (2004). Effects of high altitude exposure on the pharmacokinetics of furosemide in healthy volunteers. Int J Clin Pharmacol Ther 42:314–320
   PubMed Web of Science ®Google Scholar
• Banerjee M, Robbins D, Chen T. Targeting xenobiotic receptors PXR and CAR in human diseases. Drug Discov Today 2014. [Epub ahead of print]. doi: 10.1016/j.drudis.2014.11.011
   Google Scholar
• Bao L, Hazari S, Mehra S, et al. (2012). Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180:2490–2503
   PubMed Web of Science ®Google Scholar
• Bentires-Alj M, Barbu V, Fillet M, et al. (2003). NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22:90–97
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Park SM, Murmann AE, et al. (2012). Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 130:1787–1797
   PubMed Web of Science ®Google Scholar
• Bush JA, Li G. (2002). Regulation of the Mdr1 isoforms in a p53-deficient mouse model. Carcinogenesis 23:1603–1607
   PubMed Web of Science ®Google Scholar
• Cabrera MA, Gonzalez I, Fernandez C, et al. (2006). A topological substructural approach for the prediction of P-glycoprotein substrates. J Pharm Sci 95:589–606
   PubMed Web of Science ®Google Scholar
• Callaghan R, Crowley E, Potter S, Kerr ID. (2008). P-glycoprotein: So many ways to turn it on. J Clin Pharmacol 48:365–378
   PubMed Web of Science ®Google Scholar
• Comerford KM, Cummins EP, Taylor CT. (2004). c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res 64:9057–9061
   PubMed Web of Science ®Google Scholar
• Comerford KM, Wallace TJ, Karhausen J, et al. (2002). Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387–3394
   PubMed Web of Science ®Google Scholar
• Deng L, Lin-Lee YC, Claret FX, Kuo MT. (2001). 2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem 276:413–420
   PubMed Web of Science ®Google Scholar
• Ding Z, Yang L, Xie X, et al. (2010). Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol 136:1697–1707
   PubMed Web of Science ®Google Scholar
• Dopp JM, Moran JJ, Abel NJ, et al. (2009). Influence of intermittent hypoxia on myocardial and hepatic P-glycoprotein expression in a rodent model. Pharmacotherapy 29:365–372
   PubMed Web of Science ®Google Scholar
• Feng DD, Zhang H, Zhang P, et al. (2011). Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 15:2164–2175
   PubMed Web of Science ®Google Scholar
• Fradette C, Batonga J, Teng S, et al. (2007). Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in liver. Drug Metab Dispos 35:765–771
   PubMed Web of Science ®Google Scholar
• Fradette C, Du Souich P. (2004). Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab 5:257–271
   PubMed Web of Science ®Google Scholar
• Gao J, Xie W. (2012). Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci 33:552–558
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Shanafelt TD, Cimmino A, et al. (2009). Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 113:5568–5574
   PubMed Web of Science ®Google Scholar
• Gibson GG, Plant NJ, Swales KE, et al. (2002). Receptor-dependent transcriptional activation of cytochrome P4503A genes: Induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165–206
   PubMed Web of Science ®Google Scholar
• Hebert C, Norris K, Scheper MA, et al. (2007). High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 6:5
   PubMed Web of Science ®Google Scholar
• Ho GT, Moodie FM, Satsangi J. (2003). Multidrug resistance 1 gene (P-glycoprotein 170): An important determinant in gastrointestinal disease? Gut 52:759–766
   PubMed Web of Science ®Google Scholar
• Hua Z, Lv Q, Ye W, et al. (2006). MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia, PLoS One 1:e116
   PubMed Web of Science ®Google Scholar
• Huang J, Ma G, Muhammad I, Cheng Y. (2007). Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm. J Chem Inf Model 47:1638–1647
   PubMed Web of Science ®Google Scholar
• Ikemura K, Yamamoto M, Miyazaki S, et al. (2013). MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Mol Pharmacol 83:399–405
   PubMed Web of Science ®Google Scholar
• Kornienko AE, Guenzl PM, Barlow DP, Pauler FM. (2013). Gene regulation by the act of long non-coding RNA transcription. BMC Biol 11:59
   PubMed Web of Science ®Google Scholar
• Kovalchuk O, Filkowski J, Meservy J, et al. (2008). Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7:2152–2159
   PubMed Web of Science ®Google Scholar
• Kulshreshtha R, Ferracin M, Wojcik SE, et al. (2007). A microRNA signature of hypoxia. Mol Cell Biol 27:1859–1867
   PubMed Web of Science ®Google Scholar
• Kuo MT, Liu Z, Wei Y, et al. (2002). Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 21:1945–1954
   PubMed Web of Science ®Google Scholar
• Lazarowski A, Caltana L, Merelli A, et al. (2007). Neuronal mdr-1 gene expression after experimental focal hypoxia: A new obstacle for neuroprotection? Neurol Sci 258:84–92
   Web of Science ®Google Scholar
• Lehmann JM, McKee DD, Watson MA, et al. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–1023
   PubMed Web of Science ®Google Scholar
• Letarte L, du Souich P. (1984). Influence of hypercapnia and/or hypoxemia and metabolic acidosis on theophylline kinetics in the conscious rabbit. Am Rev Respir Dis 129:762–766
   PubMed Web of Science ®Google Scholar
• Liu M, Li D, Aneja R, et al. (2007). PO(2)-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. J Biol Chem 282:17581–17586
   PubMed Web of Science ®Google Scholar
• Lopes-Rodrigues V, Seca H, Sousa D, et al. (2014). The network of P-glycoprotein and microRNAs interactions. Int J Cancer 135:253–263
   PubMed Web of Science ®Google Scholar
• Lotz C, Kelleher DK, Gassner B, et al. (2007). Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells. Oncol Rep 17:239–244
   PubMed Web of Science ®Google Scholar
• Madanecki P, Kapoor N, Bebok Z, et al. (2013). Regulation of angiogenesis by hypoxia: The role of microRNA. Cell Mol Biol Lett 18:47–57
   PubMed Web of Science ®Google Scholar
• Maillefert JF, Maynadie M, Tebib JG, et al. (1996). Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 35:430–435
   PubMedGoogle Scholar
• Marie JP, Zittoun R, Sikic BI. (1991). Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586–592
   PubMed Web of Science ®Google Scholar
• Matouk IJ, DeGroot N, Mezan S, et al. (2007). The H19 non-coding RNA is essential for human tumor growth. PLoS One 2:e845
   PubMed Web of Science ®Google Scholar
• Matouk IJ, Mezan S, Mizrahi A, et al. (2010). The oncofetal H19 RNA connection: Hypoxia, p53 and cancer. Biochim Biophys Acta 1803:443–451
   PubMed Web of Science ®Google Scholar
• Minet E, Michel G, Mottet D, et al. (2001). c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp Cell Res 265:114–124
   PubMed Web of Science ®Google Scholar
• Musto P, Melillo L, Lombardi G, et al. (1991). High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 77:50–53
   PubMed Web of Science ®Google Scholar
• Nallamshetty S, Chan SY, Loscalzo J. (2013). Hypoxia: A master regulator of microRNA biogenesis and activity. Free Radic Biol Med 64:20–30
   PubMed Web of Science ®Google Scholar
• Ogretmen B, Safa AR. (1999). Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry 38:2189–2199
   PubMed Web of Science ®Google Scholar
• Piriyapongsa J, Jordan IK, Conley AB, et al. (2011). Transcription factor binding sites are highly enriched within microRNA precursor sequences. Biol Direct 6:61
   PubMedGoogle Scholar
• Pirker R, Wallner J, Geissler K, et al. (1991). MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708–712
   PubMed Web of Science ®Google Scholar
• Powell JR, Vozeh S, Hopewell P, et al. (1978). Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. Am Rev Respir Dis 118:229–238
   PubMed Web of Science ®Google Scholar
• Ribeiro AL, Ribeiro V. (2013). Drug metabolism and transport under hypoxia. Curr Drug Metab 14:969–975
   PubMed Web of Science ®Google Scholar
• Ritschel WA, Paulos C, Arancibia A, et al. (1996). Pharmacokinetics of meperidine in healthy volunteers after short- and long-term exposure to high altitude. J Clin Pharmacol 36:610–616
   PubMed Web of Science ®Google Scholar
• Roberts TC, Morris KV, Weinberg MS. (2014). Perspectives on the mechanism of transcriptional regulation by long non-coding RNAs. Epigenetics 9:13–20
   PubMed Web of Science ®Google Scholar
• Seca H, Lima RT, Lopes-Rodrigues V, et al. (2013). Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets 14:1135–1143
   PubMed Web of Science ®Google Scholar
• Schaich M, Soucek S, Thiede C, et al. (2005). MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 128:324–332
   PubMed Web of Science ®Google Scholar
• Seelig A. (1998). A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252–261
   PubMedGoogle Scholar
• Sharom FJ. (2011). The P-glycoprotein multidrug transporter. Essays Biochem 50:161–178
   PubMed Web of Science ®Google Scholar
• Singh DK, Prasanth KV. (2013). Functional insights into the role of nuclear-retained long noncoding RNAs in gene expression control in mammalian cells. Chromosome Res 21:695–711
   PubMed Web of Science ®Google Scholar
• Toscano-Garibay JD, Aquino-Jarquin G. (2012). Regulation exerted by miRNAs in the promoter and UTR sequences: MDR1/P-gp expression as a particular case. DNA Cell Biol 31:1358–1364
   PubMed Web of Science ®Google Scholar
• Wartenberg M, Ling FC, Muschen M, et al. (2003). Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 17:503–505
   PubMed Web of Science ®Google Scholar
• Wolfgang G, Marcus D, Ulrike S. (1998). LC: Clinical syndrome in different primaries. J Neurooncol 38:103–110
   PubMed Web of Science ®Google Scholar
• Xia S, Yu SY, Yuan XL, Xu SP. (2004). Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line. Zhonghua Yi Xue Za Zhi 84:663–666
   PubMedGoogle Scholar
• Xiang-Yang L. (2010). Pharmacokinetics study of sulfamethoxazole under hypoxia environment at high altitude [Graduation Thesis for the doctorate]. Shengyang, China: Shengyang Pharmaceutical University
   Google Scholar
• Xie J, Li DW, Chen XW, et al. (2013). Expression and significance of hypoxia-inducible factor-1alpha and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells. Oncol Lett 6:232–238
   PubMed Web of Science ®Google Scholar
• Yamada T, Takaoka AS, Naishiro Y, et al. (2013). Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Can Res 60:4761–4766
   Google Scholar
• Yang L, Li N, Wang H, et al. (2012). Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncology Rep 28:592–600
   PubMed Web of Science ®Google Scholar
• Zhang H, Li M, Han Y, et al. (2010). Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 55:2545–2551
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang L, Hu J. (2011). Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 30:55
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2008). Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38:802–832
   PubMed Web of Science ®Google Scholar